BarniS., MondinR.: Sexual dysfunction in treated breast cancer patients.Ann. Oncol.,8: 1–5, 1997.
2.
DelaneyG.P., LanglandsA.O.: Increased libido: a complication of tamoxifen therapy of male breast cancer.Breast,5: 53–54, 1996.
3.
FurrB.A., JordanV.C.: The pharmacology and clinical uses of tamoxifen.Pharmacol. Ther.,25: 127–205, 1984.
4.
HarmsenH.J., PorsiusA.J.: Endocrine therapy of breast cancer.Eur. J. Cancer Clin. Oncol.,24: 1099–1116, 1988.
5.
JaiyesimiI.A., BudzarA.U., DeckerD.A., HortobagyG.N.: Use of tamoxifen for breast cancer: twenty-eight years later.J. Clin. Oncol.,13: 513–529, 1995.
6.
KambyC., RoseC.: Metastatic pattern and response to endocrine therapy in human breast cancer.Breast Cancer Res and Treat.,8: 197–204, 1986.
7.
KiangD.T., KennedyB.J.: Tamoxifen (antiestrogen) therapy in advanced breast cancer.Ann. Inter. Med.,87: 687–690, 1977.
8.
LeonardR.C.F., LeeL., HarrisonM.E.: Impact of side-effects associated with endocrine treatments for advanced breast cancer: clinician's and patient's perceptions.Breast,5: 259–264, 1996.
9.
LitherlandS., JacksonI.M.: Anti-estrogens in the management of hormone dependent cancer.Cancer Treat. Rev.,15: 183–194, 1988.
10.
LoveR.R.: Adjuvant breast cancer therapy with tamoxifen.Female Patient: Practical Ob/Gyn Medicine,18: 71–72, 74-75, 1993.
11.
PetruE., SchmahlD.: On the role of additive hormon monotherapy with tamoxifen, Medroxyprogesterone acetate and aminoglutethimide in advanced breast cancer.Klin. Wochenschr.,65: 959–966, 1978.
12.
RoseC., MouridsenH.T.: Treatment of advanced breast cancer with tamoxifen.Recent Results Cancer Res.,91: 230–242, 1984.
13.
Thürlimann B., Beretta K., Bacchi M., Castiglione-Gertsch M., Goldhirsch A., Jungi W.F., Cavalli F., Senn H.-J., Fey M., Löhnert T. for the Swiss Group for Clinical Cancer Research (SAKK).:First-line fadrazole HCI (CGS 16949 A) versus tamoxifen in postmenopausal women with advanced breast cancer.Ann. Oncol.,7: 471–479, 1996.
